Ozempic® / Wegovy®
Semaglutide is a GLP-1 receptor agonist for type 2 diabetes and chronic weight management. It enhances insulin secretion, suppresses glucagon, and reduces appetite.
| Dosage Form | SC Injectable (Prefilled Pen) / Oral Tablet |
| Strength | 0.25 mg, 0.5 mg, 1 mg, 2 mg (injection); 3 mg, 7 mg, 14 mg (oral) |
| Storage | Store at 2–8°C before first use. After first use, store at 2–30°C for up to 56 days. |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 2 diabetes mellitus (adjunct to diet and exercise); chronic weight management (BMI ≥30 or ≥27 with comorbidity).
GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety through central appetite regulation.
Each Burrard Pharmaceuticals technology transfer package for Semaglutide includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.